publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
HER3-DXd
HERTHENA-Lung02: Phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
T-DXd
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
Edoxaban
Predictors of all-cause mortality after successful transcatheter aortic valve implantation in patients with atrial fibrillation
T-DXd
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
Edoxaban
A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial
T-DXd
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: A plain language summary of the DESTINY-Gastric01 study
Dato-DXd
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
Edoxaban
Echocardiographic parameters of left atrial structure and function and clinical outcomes at 2 years in elderly patients with atrial fibrillation — The ANAFIE echocardiographic substudy
Edoxaban
Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE registry
T-DXd
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial